American Association for the Advancement of Science, Science Translational Medicine, 537(12), 2020
DOI: 10.1126/scitranslmed.aaz3577
Full text: Unavailable
Low–tumor mutational burden prostate tumors express neoantigens that elicit T cell responses associated with favorable clinical outcomes to ipilimumab.